Trial Profile
A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Lutikizumab (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Acronyms ILLUSTRATE-K
- Sponsors AbbVie
- 17 Jan 2019 Primary endpoint has not been met. (Change in synovitis/effusion volume of the index knee), as per the results published in the Arthritis and Rheumatology
- 17 Jan 2019 Results published in the Arthritis and Rheumatology
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism